Skip to Content
Full Title A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
Protocol Number ACOSOG-Z5041
clinicaltrials.gov https://clinicaltrials.gov/show/NCT00733746
Principal Investigator(s) Sharon M Weber, MD, FACS
Division General Surgery
Status Active, not recruiting
Description

PURPOSE: This phase II trial is studying how well gemcitabine and erlotinib work when given before and after surgery in treating patients with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these drugs after surgery may kill any tumor cells that remain after surgery.

Other Clinical Trials in the Department of Surgery
webmaster@surgery.wisc.edu Copyright © 2016 The Board of Regents of the University of Wisconsin System